Here we go. Yes. And then there's a slide around the financial development.
So, it's a busy slide. But what you have here are our Q3 numbers reported freshly at the very left-hand side, showing the comparable quarter. And then the year-to-date numbers for 2025 are in the middle, followed by the comparison to last year, and then the full year 2024 on the very right-hand side. So I talked about the organic growth and the revenue of 176. And if we sort of peel the onion and work our way through the P&L, that translates into a gross margin of 69%. So we increased the gross margin by a percentage point, and we had the full impact from our price increases during Q3. And we had a slight change in the product mix. So that was a positive contribution on the operating expense side of things. We invested 82 million, which went down compared to last year, a little on sales, a little on admin, and according to plan, we invested a bit more on the R&D side. So that actually translated into a growth in EBITDA of around two percentage points. So from 49 to 50 million, despite the negative decline in revenue on the R&D side, as you can see, 24% of sales is what we have invested into R&D. So we have invested a portion of our sales into R&D, which is, of course, slightly affected by sales. However, the investments are following our plan, and we've capitalized a little bit less than normal, only 14 million this quarter, which is primarily due to the vacation period and partly also the completion of the software upgrade, which also had a slight impact on how much we capitalized on the cash flow side of things. We had a cash flow before the working capital items of 52 million, and then the working capital adjustments or impact was actually -22 million. And the majority of that was from accounts receivable. Since we had quite a number of orders placed in September.
So this is why our accounts receivable increased.
So we had an operating cash flow of 29.6 million, 30 million.
And on the investment side, we invested 22 million, both in the capitalized R&D activities as mentioned, but also investments in data storage were a significant chunk this year for server capacity for some of our new technologies. After subtracting our 4 million from finance activities, the cash flow related to that resulted in a total cash flow of 4 million. So that's really the story around our P&L. Let's take a look at the regional highlights. So in the Americas, we had 68 million on the top line coming from the Americas region, South and Northern America, which is equivalent to an organic growth of 4%. We also experienced a currency effect there, of course. I'd say in general it was carried by really good traction on the large instrument platforms and less from the smaller instruments where we saw a modest decrease. However, we also saw good traction in Latin America. So that is also positive for future growth.
Generally, I'd say, when we look at our leading indicators in collaboration with our strategic partner, we believe that we have increasing potential in the US. This was also confirmed in the half-year report of Sysmex launched yesterday in EMEA.
Likewise, sales amounted to 96 million compared to 98 million last year. That is organic growth of 1%.
I think this was actually acceptable also in light of the fact that we were up against a pretty tough comparison since we had inventory build-up in the comparable quarter last year. So, a decent single-digit growth in reality. We had reagents growth as well. Quite a bit from EMEA. However, on the hematology side, the growth was modest, very modest, with only 1%. So there was some phasing of orders on the hematology side there, but generally a good 14% growth on the reagent business for APAC.
I'd highlight that it was a soft quarter, with 13 million, reflecting 10% growth. But of course, on a very low base. This was also what we hinted at in our previous quarterly report where we had some inventory shipping. Since we are entering our program where we are manufacturing out of China.
We shipped a considerable number of parts and instrument modules to China, which impacted sales. This was the main contributor to soft sales across APAC. We also sold outside of China. And so, we do see momentum in pockets across Southeast Asia and Australia. So that is a positive outlook there.
And then I also want to emphasize that we are seeing good traction for improvement of revenue sales from our region in APAC. Of course, it's small numbers in APAC, but it gives us the confidence that our penetration and expansion in APAC on the region side is on the right track. If we cut the numbers in terms of sales per product group, the same numbers but sliced per product category, we have 93 million versus 102 on the instrument category.
And again, the contribution from the last stage of large instruments was important. And then, as I just alluded to regarding the Made in China initiative, it is very important for us to be able to participate in the market in China by manufacturing our instruments there. So that is a project that is finally also coming to an end as part of our strategy on the reagent side. I mentioned the growth of 40 million in revenue versus the 35.
So that's the 14% growth.
It's good to see that what we define as non-hematology is actually contributing with a decent single-digit healthy growth this quarter. So that is really good.
And then finally, on the software side, we recorded 43 million in revenue.
So that is also a correlation with how we're doing on the instrument side, but it is actually a decent software revenue we accomplished. We also had a contribution coming from spare parts and consumables, worth 23 million.
The key takeaways are that, as we say, yes, we've had a somewhat softer quarter with some different variations across the regions. But the underlying business is healthy, supported by the gradually expanding strategic partnership. Our focus and activities are really on training and commercial launch activities.
And so, they will be here as we start the new calendar year. I also emphasized the software upgrade without going into details prior to launch. Then I would say that it is delivering a faster and smarter workflow, and it does have a new cutting edge user interface and user experience in terms of our fifth pillar in our strategic direction or strategy, the power of focus. We also have these new areas where we expand beyond hematology, which is really the focus of deploying our Fourier Ptychographic Microscopy technology, the FPM technology. And we have reported that we are integrating this into our next generation hematology analyzer, and that is proceeding according to plan.
And based on this development, we're now also able to scan different sample formats in the context of cytology and pathology, as an example. And that is also an exciting area where we are having discussions with potential partners playing in those fields.
Taken together, it has been a solid quarter. We worked hard. But also, the R&D and now the marketing side are ramping up.
So, it's a pleasure to present the result today.
And with that, I think we should open the floor for questions.
Any questions are of course welcome. I also emphasized the software upgrade without going into details prior to launch.